SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is experiencing a notable surge amid widespread reports of potential takeover interest from multiple rivals, with community discussion focusing on the company's deeply undervalued assets and strong free cash flow as catalysts for a potential bidding war and short squeeze.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in community excitement following a recent presentation by Dr. Soon-Shiong, which highlighted Anktiva's revolutionary potential in treating and preventing cancer, with many discussing a paradigm shift in oncology and the potential for a significant short squeeze against perceived industry resistance.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending into its anticipated earnings report, with the community discussing expectations for an 18th consecutive beat and raise, fueled by its AI-powered platform and proprietary data moat, even as the stock navigates broader software sector volatility.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday (WDAY) is trending after its latest earnings release, which, despite beating estimates, triggered a significant aftermarket sell-off amidst concerns about future subscription growth and mixed reactions to its AI acquisition strategy and recent leadership changes. The community is sharply divided, with bulls viewing the dip as a buying opportunity while bears contend that AI disruption fundamentally challenges the SaaS business model, anticipating further declines for the enterprise software giant.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors digest a mixed financial update showcasing robust IBSRELA revenue growth alongside increased operating expenses for future pipeline expansion and a decline in XPHOZAH sales. The community is actively debating the significance of a new LPGA marketing partnership and a substantial insider share purchase, weighing current spending for long-term value against persistent buyout rumors.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending due to a substantial collaboration with Astellas Pharma for its prostate cancer asset, VIR-5500, supported by encouraging early-stage data and numerous analyst price target increases, leading to widespread community discussion about potential upside and a short squeeze amidst high trading volume.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association (FNMA) is generating significant discussion as investors intensely speculate on a potential announcement regarding its release from conservatorship and uplisting to the NYSE, possibly linked to upcoming political events. The community remains deeply polarized, with long-term holders highlighting recent strong earnings and expert commentary, while skeptics point to a history of delays and warn against "hopium."

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as the community eagerly anticipates its Q3 earnings, with discussions focused on updated guidance and the potential impact of a recent FDA safety notice regarding specific product lots. Persistent speculation surrounds a possible short squeeze or outright acquisition, fueled by the stock's perceived undervaluation and strategic repositioning, despite ongoing frustrations with its price action.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors anticipate upcoming earnings, with community discussion centered on its strategic pivot to AI and high-performance computing data centers, substantial backing from Google, and a notable short interest. Many believe these factors position the company for a significant short squeeze and long-term growth in the burgeoning AI infrastructure sector.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is experiencing extreme speculative interest, driven by news of its acquisition of TikTok icon Khaby Lame's core company and a recent private placement. The community is actively discussing its low float and the potential for a massive short squeeze, drawing comparisons to other highly volatile Hong Kong-based microcaps, amidst concerns about its valuation relative to its current business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Wells Fargo cut Doximity’s price target to $45 from $55 while maintaining an ‘Overweight’ rating.</li><li>Piper Sandler expressed confidence in Doximity’s platform despite a bleak near-term outlook.</li><li>The&nbsp;company expects Q4 revenue in the range of $143 million to $144 million, compared to $185.1 million it reported in the third quarter.</li></ul>Shares of Doximity Inc. (DOCS) slumped 35% in premarket trading on Friday, following a series of brokerage actions amid regulatory pressures and lower-than-expected fourth-quarter revenue guidance.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/DOCS">DOCS stock </a>will fall to its lowest levels since November 2023.<h2 class="st-heading-2">Competition, Regulatory Pressure Are Key Risks</h2>Wells Fargo cut Doximity’s price target to $45 from $55 while maintaining an ‘Overweight’ rating, according to The Fly. The firm said limited visibility was already a concern ahead of the third quarter, but additional caution from pharmaceutical clients led to fewer upfront commitments and slower conversions than expected. While the stock’s decline to around $20 appears excessive, the brokerage noted that investor sentiment could take time to reboundPiper Sandler slashed the company’s price target to $40 from $70, while maintaining an ‘Overweight’ rating. Analyst Jessica Tassan noted that Doximity is off to a slow start in 2026, with weak Q2 and Q3 bookings, as market growth slowed to about 5% and sales cycles lengthened amid pharma’s macro-driven caution. Despite the bleak near-term outlook, the firm expressed confidence in Doximity’s platform's strength.Needham analyst Scott Berg lowered Doximity’s price target to $55 from $75 while maintaining a ‘Buy’ rating, citing competition and regulatory pressures as key risks even if the sell-off appears overdone. Although the Q4 guidance is disappointing, Needham expects budgets to improve through 2026.<h2 class="st-heading-2">Client Uncertainty Around Policy Changes</h2>In a call with analysts on Thursday, Doximity stated that client uncertainty around recent policy changes and the Most Favored Nation agreement affected its annual budgets.“First, we saw multiple customers deploy a lower percentage of their annual budgets upfront than usual as 2026 planning wasn't fully complete and some funds remained unreleased,” said Timothy Cabral, a member of the board.“Second, this uncertainty resulted in many deals we normally have signed by December 31 being delayed and pushed into our fiscal Q4. This is evident in our January pharma bookings growth rate, which is the best we've seen since going public,” Cabral added.Doximity’s Q3 revenue grew 10% to $185.1 million, but its diluted earnings per share declined to $0.31 from $0.37. The company expects Q4 revenue in the range of $143 million to $144 million and FY 2026 revenue between $642.5 million and $643.5 million. The company also announced a share repurchase program of up to $500 million of its Class A common stock.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market crash, retail sentiment flipped to “extremely bullish” from “bearish” over the past 24 hours, amid “extremely high” message volumes.<img src="https://news.stocktwits-cdn.com/DOCS_jpg_2d9473084f.webp" alt="DOCS.jpg">Users felt that the selloff was an “overreaction”.<stembedurl>https://stocktwits.com/Noisy/message/644244636</stembedurl><stembedurl>https://stocktwits.com/giuseppe8469/message/644205757</stembedurl>Over the past year, the stock has declined by around 43%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/amzn-stock-falls-below-long-term-moving-average-slumps-premarket/cZbFfDJR4nC">AMZN Stock Falls To 8-Month Lows In Pre-Market After Declining Below 200-DMA For First Time Since October</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Why Did DOCS Stock Plunge 35% In Pre-Market Today?

Multiple brokerages cut their price target on the stock after Doximity reported a fall in third-quarter earnings and a soft fourth-quarter revenue outlook.

Equity

Shares of Teladoc Health Inc. surged as much as 3% on Tuesday morning, peaking at levels last seen a week ago before trimming some gains later in the day.&nbsp;The rise followed an announcement of a new collaboration with Amazon.com, aimed at expanding access to Teladoc’s programs, including those for diabetes, hypertension, pre-diabetes, and weight management, through Amazon’s Health Benefits Connector.&nbsp;No further details about the collaboration’s terms were provided.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TDOC_sentiment_and_message_volume_Jan_14_736f372c12.png" alt="TDOC sentiment and message volume Jan 14.png" width="1318" height="324"><figcaption>TDOC sentiment and message volume Jan 14 as of 10:20 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment shifted dramatically to ‘extremely bullish’ from ‘bearish’ a day ago, with message volume hitting its highest levels in the past month.&nbsp;Some retail investors expressed optimism, with one speculating that this partnership could pave the way for an acquisition by Amazon, which has been expanding its presence in telehealth services.<stembedurl>https://stocktwits.com/rxptgh/message/599945090</stembedurl><stembedurl>https://stocktwits.com/Genuisboltz/message/599941043</stembedurl><stembedurl>https://stocktwits.com/Genuisboltz/message/599941043</stembedurl>Since 2018, Amazon has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-after-amazon-medical-one-rival-service/cJ4Z1asRfj">steadily</a> built out its healthcare offerings, which now include Amazon Care (a hybrid virtual and in-person care service) and One Medical (a telehealth platform providing pay-per-visit care and membership options).&nbsp;The new collaboration builds on Teladoc and Amazon’s partnership that began in 2022 to provide virtual care through Alexa devices.Teladoc, which experienced rapid growth during the COVID-19 pandemic, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/teladoc-falls-withdraws-financial-outlook-retail-bearish/c7HhdmtRRR">struggled</a> to maintain that momentum in the face of rising competition and poor financial performance.&nbsp;Following the ouster of CEO Jason Gorevic last year, the company has been trying to chart a recovery path.&nbsp;Despite the recent gains, its stock remains 97% off its all-time high during the pandemic.&nbsp;With a current short interest of 13.2%, Teladoc has gained just over 3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, a Teladoc logo is seen on a smartphone screen and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Teladoc’s New Amazon Tie-Up Sparks Retail Sentiment Surge Even As Stock Swings Wildly

Following the ouster of CEO Jason Gorevic last year, the telehealth company has been trying to chart a recovery path.

Global X Funds - Global X HealthTech ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

EDOC
Global X Funds - Global X Telemedicine & Digital Health ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EDOC News

EDOCGlobal X Funds - Global X Telemedicine & Digital Health ETF